60 References Li, H. et al. (2020) Mucosal or systemic microbiota exposures shape the B cell repertoire. Nature 584, 274278. doi: 10.1038/s41586-020-2564-6. Salim, S.Y. and Söderholm, J.D. (2011) Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm. Bowel Dis. 17, 362-381. doi: 10.1002/ibd.21403. Alexander, K.T. et al. (2021) Human Microbiota Flagellins Drive Adaptive Immune Responses in Crohn’s Disease. Gastroenterology 161, 522-535. doi: 10.1053/j.gastro.2021.03.064. Vogl, T. et al. (2021) Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota. Nat. Med. 27, 1442-1450. doi: 10.1038/s41591-021-01409-3. Chang, J.T. (2020). Pathophysiology of Inflammatory Bowel Diseases. N. Engl. J. Med. 383, 2652-2664. doi: 10.1056/NEJMra2002697. Ananthakrishnan, A.N. et al (2018) Environmental triggers in IBD: a review of progress and evidence. Nat. Rev. Gastroenterol. Hepatol. 15, 39-49. doi: 10.1038/nrgastro.2017.136. De Lange, K.M. et al. (2017) Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256-261. doi: 10.1038/ng.3760. de Souza, H.S.P. et al. (2017) The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat. Rev. Gastroenterol. Hepatol. 14, 739-749. doi: 10.1038/nrgastro.2017.110. Cosnes, J. et al (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140, 1785-1794. doi: 10.1053/j.gastro.2011.01.055. Maaser, C. et al. (2019) ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohns. Colitis. 13, 144-164. doi: 10.1093/eccojcc/jjy113. Torres, J. et al (2017) Crohn’s disease. Lancet 389, 1741-1755. doi: 10.1016/S0140-6736(16)31711-1. Ungaro, R. et al (2017) Ulcerative colitis. Lancet 389, 1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Ferrante, M. et al. (2007) New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56, 1394-1403. doi: 10.1136/gut.2006.108043. Torres, J. et al. (2020) Serum Biomarkers Identify Patients WhoWill Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology 159, 96-104. doi: 10.1053/j.gastro.2020.03.007. Mitsuyama, K. et al. (2016) Antibody markers in the diagnosis of inflammatory bowel disease. World J. Gastroenterol. 22, 1304-1310. doi: 10.3748/wjg.v22.i3.1304. Lee, S.H. et al. (2021) Anti-Microbial Antibody Response is AssociatedWith Future Onset of Crohn’s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology 161, 1540-1551. doi: 10.1053/j.gastro.2021.07.009. de Souza, H.S.P. and Fiocchi, C. (2016) Immunopathogenesis of IBD: current state of the art. Nat. Rev. Gastroenterol. Hepatol. 13, 13-27. doi: 10.1038/nrgastro.2015.186. Hooper, L.V. et al. (2012) Interactions between the microbiota and the immune system. Science 336, 1268-1273. doi: 10.1126/science.1223490. Franzosa, E.A. et al. (2019) Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 4, 293-305. doi: 10.1038/s41564-018-0306-4. De Lange, K.M. et al. (2017) Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256-261. doi: 10.1038/ng.3760. Sewell, G.W. et al. (2009) The immunopathogenesis of Crohn’s disease: a three-stage model. Curr. Opin. Immunol. 21, 506-513. doi: 10.1016/j.coi.2009.06.003. Neurath, M.F. (2019) Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat. Immunol. 20, 970-979. doi: 10.1038/s41590-019-0415-0. Chapter 2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
RkJQdWJsaXNoZXIy MjY0ODMw